Segmentation by type classifies In Vivo Pharmacology Model offerings into five distinct groups: rodent models, non‑rodent models, genetically engineered models, disease‑specific models, and humanized models. Rodent models—primarily mice and rats—capture the largest share, roughly 45 % of market revenue, due to their cost efficiency and extensive historical data sets. Non‑rodent models (e.g., canine, swine, primate) contribute about 20 %, reflecting their utility in pharmacokinetic scaling and safety pharmacology where rodent physiology is insufficient. Genetically engineered models, encompassing knockout, knock‑in, and CRISPR‑edited lines, hold 15 % of the market, driven by precision‑medicine initiatives that require target‑specific phenotypes. Disease‑specific models—such as chemically induced or surgically created disease states—account for 12 %, supporting translational studies that mimic human pathology. Humanized models, which incorporate human genes, cells, or tissues, represent the remaining 8 %, offering unique insights for immuno‑oncology and infectious disease research. This type‑based taxonomy clarifies how each model class contributes to the aggregate market valuation.